Browse > Article
http://dx.doi.org/10.14776/piv.2016.23.1.31

Clinical Characteristics, Prognostic Factors and Influence of Prophylaxis in Children with Pneumocystis jirovecii Pneumonia  

Kim, Seohee (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
Yoo, Reenar (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
Sung, Hungseop (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Jina (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
Pediatric Infection and Vaccine / v.23, no.1, 2016 , pp. 31-39 More about this Journal
Abstract
Purpose: The aim of this study was to investigate the prognostic factors for Pneumocystis jirovecii pneumonia (PCP) and to evaluate the influence of PCP prophylaxis in pediatric patients. Methods: From January 2002 to April 2015, patients aged <18 years with a diagnosis of confirmed PCP at our institute were reviewed retrospectively. Clinical characteristics and outcomes were compared according to the groups with or without PCP prophylaxis. Risk factors associated with PCP-related death were analyzed by logistic regression analysis. Results: During study period, a total of 24 patients were diagnosed with PCP by immunofluorescence assay and/or PCR. The median age of the patients was 5 years (range, 3 months-18 years) and 23 (96%) had immunocompromised conditions including hematologic disorders with or without hematopoietic stem cell transplantation (n=15), solid organ transplantation (n=4), and primary immune deficiency (n=4). Most common presenting symptoms were tachypnea and cough (92%, each). At the time of diagnosis, 79% (19/24) and 25% (6/24) suffered from respiratory failure and multi-organ dysfunction syndrome (MODS), respectively. Mechanical ventilation was required in 8 (33%) patients and 5 (21%) patients died of PCP. Multivariate analysis showed that MODS at initial presentation was an indicator of poor prognosis (OR, 17.1 [95% CI 1.13-257.67]; P=0.04). Compared to the patients without PCP prophylaxis, the frequency of MODS at diagnosis, need for mechanical ventilation and length of hospital days were significantly less common in the children who received PCP prophylaxis. Conclusions: MODS at presentation was a significant predictor for poor outcome and PCP prophylaxis could alleviate the clinical courses of pediatric PCP. Prospective study will be mandatory to determine the risk factors for development and deterioration of PCP in children.
Keywords
Pneumocystis jirovecii Pneumonia; Prophylaxis; Prognostic factor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Poulsen A, Demeny AK, Bang Plum C, Gjerum Nielsen K, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001;37:20-3.   DOI
2 Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238.   DOI
3 Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001;286:2450-60.   DOI
4 Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20.   DOI
5 Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014;10:Cd005590.
6 Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIVinfected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-9.   DOI
7 Proudfoot R, Cox R, Phillips B, Wilne S. UK survey of Pneumocystis jirovecii pneumonia (PJP) prophylaxis use in paediatric oncology patients. Arch Dis Child 2015;100:115.   DOI
8 Shankar SM, Nania JJ. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs 2007;9:301-9.   DOI
9 Wang XL, Wang XL, Wei W. Retrospective study of Pneumocystis pneumonia over half a century in mainland China. J Med Microbiol 2011;60:631-8.   DOI
10 Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006;25:382-8.   DOI
11 Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-31.   DOI
12 Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 2014;69:88-95.   DOI
13 Tamai K, Tachikawa R, Tomii K, Nagata K, Otsuka K, Nakagawa A, et al. Prognostic value of bronchoalveolar lavage in patients with non-HIV Pneumocystis pneumonia. Intern Med 2014;53:1113-7.   DOI
14 Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis:the relative contribution of non-adherence and drug failure. AIDS 2000;14:2559-66.   DOI
15 World Health Organization: Programme for the Control of Acute Respiratory infections. Acute respiratory infection in children: case management in small hospitals in developing countries. A manual for doctors and other senior health workers. Geneva, Switzerland: World Health Organization, 1990.
16 Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6:2-8.   DOI
17 Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 2015;15:190-9.   DOI
18 Zajac-Spychala O, Gowin E, Fichna P, Wysocki J, Fichna M, Kowala-Piaskowska A, et al. Pneumocystis pneumonia in children - the relevance of chemoprophylaxis in different groups of immunocompromised and immunocompetent paediatric patients. Cent Eur J Immunol 2015;40:91-5.
19 Saltzman RW, Albin S, Russo P, Sullivan KE. Clinical conditions associated with PCP in children. Pediatr Pulmonol 2012;47:510-6.   DOI
20 Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 2014;20:412-6.   DOI
21 Laursen AL, Mogensen SC, Andersen HM, Andersen PL, Ellermann-Eriksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001;123:239-46.   DOI
22 Jensen AM, Lundgren JD, Benfield T, Nielsen TL, Vestbo J. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 1995;108:411-4.   DOI
23 Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995;273:1197-202.   DOI
24 Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998;113:1215-24.   DOI
25 Nahimana A, Rabodonirina M, Zanetti G, Meneau I, Francioli P, Bille J, et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis 2003;188:1017-23.   DOI
26 Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015;4:Cd006150.
27 Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011;55:4613-8.   DOI
28 Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 2005;25:651-5.
29 Guo F, Chen Y, Yang SL, Xia H, Li XW, Tong ZH. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One 2014;9:e101943.   DOI
30 Gracia JD, Miravitlles M, Mayordomo C, Ferrer A, Alvarez A, Bravo C, et al. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Chest 1997;111:1180-6.   DOI
31 Leigh TR, Gazzard BG, Rowbottom A, Collins JV. Quantitative and qualitative comparison of DNA amplification by PCR with immunofluorescence staining for diagnosis of Pneumocystis carinii pneumonia. J Clin Pathol 1993;46:140-4.   DOI
32 Colangelo G, Baughman RP, Dohn MN, Frame PT. Followup bronchoalveolar lavage in AIDS patients with Pneumocystis carinii pneumonia. Pneumocystis carinii burden predicts early relapse. Am Rev Respir Dis 1991;143:1067-71.   DOI